These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 31305170

  • 1. Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence.
    Santambrogio E, Nicolosi M, Vassallo F, Castellino A, Novo M, Chiappella A, Vitolo U.
    Expert Rev Hematol; 2019 Sep; 12(9):787-796. PubMed ID: 31305170
    [Abstract] [Full Text] [Related]

  • 2. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options.
    Ferreri AJ, Assanelli A, Crocchiolo R, Ciceri F.
    Hematol Oncol; 2009 Jun; 27(2):61-70. PubMed ID: 19247977
    [Abstract] [Full Text] [Related]

  • 3. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte.
    Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rose C, Tilly H, Sonet A, Lederlin P, Attal M, Brière J, Reyes F.
    Ann Oncol; 2000 Jun; 11(6):685-90. PubMed ID: 10942056
    [Abstract] [Full Text] [Related]

  • 4. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
    Kansara R.
    Curr Treat Options Oncol; 2018 Sep 10; 19(11):52. PubMed ID: 30203318
    [Abstract] [Full Text] [Related]

  • 5. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
    Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y.
    Cancer; 2002 Aug 01; 95(3):576-80. PubMed ID: 12209750
    [Abstract] [Full Text] [Related]

  • 6. Results of combined-modality therapy for primary and secondary malignant lymphoma of the central nervous system (CNS).
    Kawamura T, Koga S, Okamoto M, Kanno T, Iwamura H.
    Radiat Med; 2001 Aug 01; 19(3):145-9. PubMed ID: 11467381
    [Abstract] [Full Text] [Related]

  • 7. How I treat patients with aggressive lymphoma at high risk of CNS relapse.
    Chin CK, Cheah CY.
    Blood; 2017 Aug 17; 130(7):867-874. PubMed ID: 28611025
    [Abstract] [Full Text] [Related]

  • 8. Prevention and management of secondary central nervous system lymphoma.
    Bobillo S, Khwaja J, Ferreri AJM, Cwynarski K.
    Haematologica; 2023 Mar 01; 108(3):673-689. PubMed ID: 36384246
    [Abstract] [Full Text] [Related]

  • 9. Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group project.
    Bromberg JE, Doorduijn JK, Illerhaus G, Jahnke K, Korfel A, Fischer L, Fritsch K, Kuittinen O, Issa S, van Montfort C, van den Bent MJ.
    Haematologica; 2013 May 01; 98(5):808-13. PubMed ID: 23144196
    [Abstract] [Full Text] [Related]

  • 10. The risk of CNS involvement in aggressive lymphomas in the rituximab era.
    Benevolo G, Chiappella A, Vitolo U.
    Expert Rev Hematol; 2013 Dec 01; 6(6):643-52. PubMed ID: 24168678
    [Abstract] [Full Text] [Related]

  • 11. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL, Marton E, Plander M, Gyánó G, Czumbil L, Tóth C.
    Orv Hetil; 2009 Oct 18; 150(42):1937-44. PubMed ID: 19812012
    [Abstract] [Full Text] [Related]

  • 12. Central Nervous System Involvement of Natural Killer and T Cell Neoplasms.
    Aaroe AE, Nevel KS.
    Curr Oncol Rep; 2019 Mar 27; 21(5):40. PubMed ID: 30919085
    [Abstract] [Full Text] [Related]

  • 13. Secondary central nervous system lymphoma.
    Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y.
    Int J Hematol; 2006 Aug 27; 84(2):128-35. PubMed ID: 16926134
    [Abstract] [Full Text] [Related]

  • 14. Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies.
    Orellana-Noia V, Abousaud A.
    Curr Treat Options Oncol; 2022 Oct 27; 23(10):1443-1456. PubMed ID: 36127571
    [Abstract] [Full Text] [Related]

  • 15. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience.
    Curry LD, Munker R, Li N, Yan D, Pryor P, Nozad S, Keller P, Monohan GP, Iragavarapu C, Krem MM.
    Ann Hematol; 2023 Jan 27; 102(1):141-154. PubMed ID: 36367559
    [Abstract] [Full Text] [Related]

  • 16. Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis.
    Hollender A, Kvaloy S, Lote K, Nome O, Holte H.
    Eur J Cancer; 2000 Sep 27; 36(14):1762-8. PubMed ID: 10974623
    [Abstract] [Full Text] [Related]

  • 17. Relapse of primary CNS lymphoma after more than 10 years in complete remission.
    Herrlinger U, Hebart H, Kanz L, Dichgans J, Weller M.
    J Neurol; 2005 Nov 27; 252(11):1409-10. PubMed ID: 15895304
    [No Abstract] [Full Text] [Related]

  • 18. Therapeutic management of refractory or relapsed primary central nervous system lymphomas.
    Reni M, Ferreri AJ.
    Ann Hematol; 2001 Nov 27; 80 Suppl 3():B113-7. PubMed ID: 11757691
    [Abstract] [Full Text] [Related]

  • 19. CNS prophylaxis in aggressive B-cell lymphoma.
    Wilson MR, Bobillo S, Cwynarski K.
    Hematology Am Soc Hematol Educ Program; 2022 Dec 09; 2022(1):138-145. PubMed ID: 36485105
    [Abstract] [Full Text] [Related]

  • 20. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
    Ollila TA, Olszewski AJ.
    Curr Treat Options Oncol; 2018 Jun 21; 19(8):38. PubMed ID: 29931605
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.